VOLITIONRX LTD. news, videos and press releases - Page 4
For more news please use our advanced search feature.
VOLITIONRX LTD. - More news...
VOLITIONRX LTD. - More news...
- VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update
-
VolitionRx - executive interview
- New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis
- VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts
- National Taiwan University Hospital Presents Data on Nu.Q™ Assay Performance at the World Conference on Lung Cancer
- Volition Launches Nu.Q™ Vet Cancer Screening Test in the U.S.
-
VolitionRx - executive interview
- Volition Veterinary Presents Expert Report Ahead of First Product Launch
-
VolitionRx – vet data interview
- Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conference
- Volition Veterinary Diagnostics Development LLC to Present Product Data Regarding its Nu.Q™ Vet Cancer Screening Test at the 2020 VCS Virtual Annual Conference
-
VolitionRx - executive interview
-
VolitionRx - executive interview
- Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test
- Cotterford Co. Ltd. Sends Letter to VolitionRX Following Annual Meeting Vote Results Confirming Deep-Seated Discontent Among Shareholders
- VolitionRx Releases Business Update Video and Announces Addition to the Russell 3000® and Russell Microcap® Indexes
- Cotterford Co. Ltd. Sends Letter to Board of VolitionRX
- Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference
- VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock
- VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
- VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
-
VolitionRx - executive interview
- Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers
- Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies
-
Executive interview – VolitionRx
- Volition Unveils Its Epigenetic Toolbox
- Volition Develops a New Improved Nu.Q™ Assay Format
- VolitionRx Completes Acquisition of Octamer GmbH
- VolitionRx Limited Announces Strategic Acquisition
- VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test
